Agrasen Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.98 M
as on 05-07-2024
- Company Age 15 Year, 1 Day
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 9.00 Cr
as on 05-07-2024
- Revenue 280.63%
(FY 2022)
- Profit 754.14%
(FY 2022)
- Ebitda 105.48%
(FY 2022)
- Net Worth 0.50%
(FY 2022)
- Total Assets 0.19%
(FY 2022)
About Agrasen Biotech
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.98 M.
The company has closed loans amounting to ₹9.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Neha Agarwal and Nitin Agarwal serve as directors at the Company.
- CIN/LLPIN
U20129UP2009PTC039080
- Company No.
039080
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Dec 2009
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Agra, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Agrasen Biotech Private Limited offer?
Agrasen Biotech Private Limited offers a wide range of products and services, including Real Estate Agent & Property Dealers, Real Estate Consulting Service, Financial Service, Finance Consultant, Metal Castings, Investment Castings, Project Finance Consultants, Business Project Financing, Business Finance Consultants, Investment Service.
Who are the key members and board of directors at Agrasen Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Agarwal  | Director | 24-Dec-2009 | Current |
| Neha Agarwal | Director | 08-Sep-2023 | Current |
Financial Performance of Agrasen Biotech.
Agrasen Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 280.63% increase. The company also saw a substantial improvement in profitability, with a 754.14% increase in profit. The company's net worth moved up by a moderate rise of 0.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agrasen Biotech?
In 2018, Agrasen Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Murlimanohar Infradevelopers Private LimitedActive 9 years 4 months
Nitin Agarwal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Dec 2017 | ₹9.00 Cr | Satisfied |
How Many Employees Work at Agrasen Biotech?
Unlock and access historical data on people associated with Agrasen Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agrasen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agrasen Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
